Abstract:<p>FGF23 is a critical factor in chronic kidney disease (CKD), with elevated levels causing alterations in mineral metabolism and increased odds for mortality. Patients with CKD develop anemia as the kidneys progressively lose the ability to produce erythropoietin (EPO). Anemia is a potent driver of FGF23 secretion; therefore, a HIF‐PHI (hypoxia‐inducible factor prolyl hydroxylase inhibitor) currently in clinical trials to elevate endogenous EPO to resolve anemia, was tested for effects on iron utilization and FGF23‐related parameters in a CKD mouse model. Mice were fed either a casein control diet or an adenine‐containing diet to induce CKD. The CKD mice had markedly elevated iFGF23 and blood urea nitrogen (BUN), hyperphosphatemia, and anemia. Cohorts of mice were then treated with a patient‐equivalent dose of BAY 85–3934 ('BAY'; Molidustat) which elevated EPO and completely resolved aberrant CBCs in the CKD mice. iFGF23 was elevated in vehicle‐treated CKD mice (120‐fold), whereas circulating iFGF23 was significantly attenuated (>60%) in the BAY‐treated CKD mice. The BAY‐treated mice with CKD also had reduced BUN but there was no effect on renal vitamin D metabolic enzyme expression. Consistent with increased EPO, bone marrow Erfe, Transferrin receptor (Tfrc), and EpoR mRNAs were increased in BAY‐treated CKD mice, and in vitro hypoxic marrow cultures increased FGF23 with direct EPO treatment. Liver Bmp‐6 and hepcidin expression were downregulated in all BAY treated groups. Femur trabecular parameters and cortical porosity were not worsened with BAY administration. In vitro, differentiated osteocyte‐like cells exposed to an iron chelator to simulate iron depletion/hypoxia increased FGF23; repletion with holo‐transferrin completely suppressed FGF23 and normalized Tfrc1. Collectively, these results support that resolving anemia using a HIF‐PHI during CKD was associated with lower BUN and reduced FGF23, potentially through direct restoration of iron utilization, thus providing modifiable outcomes beyond improving anemia for this patient population.</p><p>This article is protected by copyright. All rights reserved.</p>

Gene therapy targeting sustained FGF23-ERK signaling alleviates kidney inflammation

Dynamic Single Cell Transcriptomics Defines Kidney FGF23/KL Bioactivity and Novel Segment-Specific Inflammatory Targets

C-Terminal Fragment of Fibroblast Growth Factor (FGF)-23 Improves Heart Function in Murine Models of High intact FGF23

FGF23 from bench to bedside

A Novel Distal Enhancer Mediates Inflammation-, PTH-, and Early Onset Murine Kidney Disease-Induced Expression of the Mouse Fgf23 Gene

FGF23 as a Potential Pathophysiological Factor in Peripheral Arterial Disease Associated with Chronic Kidney Disease

FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1/CXCR4 signaling

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)

Orphan nuclear receptor ERR-γ regulates hepatic FGF23 production in acute kidney injury

Delineating oncogene/tumor suppressor interactions in human mammary epithelial cells

Excessive fibroblast growth factor 23 promotes renal fibrosis in mice with type 2 cardiorenal syndrome

FGF23 protein expression in coronary arteries is associated with impaired kidney function

Systemic Jak1 activation provokes hepatic inflammation and imbalanced FGF23 production and cleavage

Correction: FGF1 ΔHBS ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation

FGF23 signalling and physiology

Pathophysiological Implications of Imbalances in Fibroblast Growth Factor 23 in the Development of Diabetes

FGF-23: More than a regulator of renal phosphate handling?

The HIF‐PHI BAY 85‐3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model

Immunofluorescent evidence of Proteus mirabilis swarm cell formation on sterilized rat feces

The role of FGF23 in CKD—with or without Klotho

FGF23 Actions on Target Tissues—With and Without Klotho